International Pharma Business

129 posts

Conditional Approval and Pricing of New Drugs – Asrar Qureshi’s Blog Post #1313

Asrar Qureshi’s blog delves into the complex journey of health innovations from discovery to patient access, highlighting the significant costs and time involved in drug development. It emphasizes the need for a collaborative approach between pharmaceutical companies and governments to address pricing, making life-saving medications accessible while managing risks and uncertainties effectively.
Share
View Post
  • 6 min

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 2 – Asrar Qureshi’s Blog Post #1292

This blog post by Asrar Qureshi examines the exit of multinational pharmaceutical companies from Pakistan, analyzing its historical context and impacts on the healthcare system. While local firms maintain medicine availability, concerns arise regarding innovation and clinical research. The challenge remains to balance local manufacturing capabilities with the need for multinational investment and research.
Share
View Post
  • 6 min

Doctors & Pharma Industry – Part 2 of 2 – Asrar Qureshi’s Blog Post #1218

Asrar Qureshi’s Blog Post #1218 addresses the complex relationship between pharmaceutical companies and doctors, emphasizing the need for ethical conduct in Pakistan’s healthcare system. It outlines a Code of Conduct for both sectors, aiming to balance industry collaboration with patient welfare, maintaining professionalism while avoiding conflicts of interest.
Share
View Post
  • 5 min

Pharma Marketing by 2030 – Asrar Qureshi’s Blog Post #1148

Asrar Qureshi’s Blog Post #1148 outlines anticipated changes in pharmaceutical marketing by 2030, emphasizing a hybrid omnichannel approach and AI integration in sales. The role of Medical Affairs will grow, and compliance will become real-time. In Pakistan, increased digital engagement and regulatory improvements will shape marketing strategies, enhancing patient support programs.
Share
View Post
  • 5 min

Recent Drug Safety Alerts – Asrar Qureshi’s Blog Post #1125

Asrar Qureshi’s Blog Post 1125 discusses post-marketing surveillance and pharmacovigilance efforts in reporting adverse drug reactions. It highlights recent FDA warnings about cetirizine, scopolamine patches, and mRNA COVID-19 vaccines concerning severe side effects, urging that this information be treated as essential for discussions among healthcare professionals.
Share
View Post
  • 5 min

Why Pakistan’s Pharmaceutical Exports Lag Behind and How to Fix It– Asrar Qureshi’s Blog Post #1124

Pakistan’s pharmaceutical exports are notably low despite having a robust industry, with challenges including inadequate investment in facilities, lack of international certifications, inconsistent compliance with quality standards, and insufficient market intelligence. Strategic reforms, including regulatory improvements and investment in workforce development, are essential for enhancing exports and achieving global competitiveness.
Share
View Post
  • 6 min

Formation of PharmEx Pakistan – Too Late, Too Little? – Asrar Qureshi’s Blog Post #1123

The Ministry of Commerce in Pakistan is launching PharmEx Pakistan to boost pharmaceutical exports, aiming to increase annual exports from $700 million to $3 billion. This public-private initiative, modeled after India’s Pharmexcil, seeks to enhance regulatory compliance and global visibility for Pakistani pharmaceuticals, while facing challenges in international competitiveness.
Share
View Post
  • 5 min

Colossal Wrongdoings by Big Pharma – Servier – Asrar Qureshi’s Blog Post #1094

Benfluorex, marketed as Mediator, was widely prescribed for diabetes and weight loss in France until its 2009 withdrawal due to severe health risks, causing 500-2,000 deaths. Dr. Irène Frachon’s investigation revealed systemic regulatory failures and corporate negligence. The scandal prompted significant reforms in France’s drug safety oversight to enhance transparency and accountability.
Share
View Post
  • 5 min

Colossal Wrongdoings by Big Pharma – Ranbaxy Scandal – Asrar Qureshi’s Blog Post #1093

The Ranbaxy scandal illustrates significant fraud within a major Indian pharmaceutical company that misled regulatory bodies and compromised drug safety. Whistleblower Dinesh Thakur’s revelations led to a $500 million settlement, exposing flaws in oversight and raising questions about generics. It’s a vital lesson on ethical standards and regulatory vigilance in the industry.
Share
View Post
  • 6 min

Colossal Wrongdoings by Big Pharma – Insulin Price Gouging – Asrar Qureshi’s Blog Post #1092

The blog post discusses the insulin price gouging crisis that began around 2000, with prices soaring due to manipulation by major manufacturers Eli Lilly, Novo Nordisk, and Sanofi. This crisis has significant implications for patients’ health and financial well-being, highlighting ethical issues in pharmaceutical capitalism and calling for urgent reform to ensure accessibility.
Share